Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer

Breast Cancer Research and Treatment

Volumn 133, Issue 1, 2012, Pages 145-159

  Ito, Tokiko ^a   Kamijo, Shinobu ^a   Izumi, Hiroto ^b   Kohno, Kimitoshi ^b   Amano, Jun ^a   Ito, Ken Ichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Breast cancer; Crosstalk; Endocrine therapy; YB 1

Indexed keywords

ANTIESTROGEN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; FLUOROURACIL; FULVESTRANT; GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; STEROID RECEPTOR COACTIVATOR 3; TAMOXIFEN; Y BOX BINDING PROTEIN 1;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER HORMONE THERAPY; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL STRAIN MCF 7; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ESTROGEN RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; UPREGULATION; VECTOR CONTROL; WILD TYPE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUCIFERASES, RENILLA; RECEPTOR CROSS-TALK; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; TAMOXIFEN; Y-BOX-BINDING PROTEIN 1;

EID: 84860421207     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1731-8     Document Type: Article

References (57)

1. Y Yarden 2001 Biology of HER2 and its importance in breast cancer Oncology 61 Suppl 2 1 13 11694782 10.1159/000055396 1:CAS:528: DC%2BD3MXovFWjsLw%3D (Pubitemid 33033419)
2. RI Nicholson RA McClelland JF Robertson JM Gee 1999 Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer Endocr Relat Cancer 6 3 373 387 10516852 10.1677/erc.0.0060373 1:CAS:528:DyaK1MXmsVOmt7k%3D (Pubitemid 29459785)
3. J Shou S Massarweh CK Osborne AE Wakeling S Ali H Weiss R Schiff 2004 Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer J Natl Cancer Inst 96 12 926 935 15199112 10.1093/jnci/djh166 1:CAS:528:DC%2BD2cXltVWmtLY%3D (Pubitemid 38868139)
4. CK Osborne V Bardou TA Hopp GC Chamness SG Hilsenbeck SA Fuqua J Wong DC Allred GM Clark R Schiff 2003 Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer J Natl Cancer Inst 95 5 353 361 12618500 10.1093/jnci/95.5.353 1:CAS:528:DC%2BD3sXivVeqsrg%3D (Pubitemid 36395255)
5. CK Osborne J Shou S Massarweh R Schiff 2005 Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer Clin Cancer Res 11 2 Pt 2 865s 870s 15701879 1:CAS:528:DC%2BD2MXislWgu7k%3D (Pubitemid 40111098)
6. R Schiff S Massarweh J Shou CK Osborne 2003 Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response Clin Cancer Res 9 1 Pt 2 447S 454S 12538499 1:CAS:528:DC%2BD3sXnt1yjsw%3D%3D (Pubitemid 36105786)
7. R Schiff SA Massarweh J Shou L Bharwani SK Mohsin CK Osborne 2004 Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance Clin Cancer Res 10 1Pt 2 331S 336S 14734488 10.1158/1078-0432.CCR-031212 1:CAS:528:DC%2BD2cXkvF2ksw%3D%3D (Pubitemid 38116639)
8. H Sakura T Maekawa F Imamoto K Yasuda S Ishii 1988 Two human genes isolated by a novel method encode DNA-binding proteins containing a common region of homology Gene 73 2 499 507 2977358 10.1016/0378-1119(88)90514-8 1:CAS:528:DyaL1MXlt1Oqt7s%3D (Pubitemid 19043281)
9. DK Didier J Schiffenbauer SL Woulfe M Zacheis BD Schwartz 1988 Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box Proc Natl Acad Sci USA 85 19 7322 7326 3174636 10.1073/pnas.85.19.7322 1:CAS:528:DyaL1MXktlCnsr4%3D
10. M Furukawa T Uchiumi M Nomoto H Takano RI Morimoto S Naito M Kuwano K Kohno 1998 The role of an inverted CCAAT element in transcriptional activation of the human DNA topoisomerase IIalpha gene by heat shock J Biol Chem 273 17 10550 10555 9553115 10.1074/jbc.273.17.10550 1:CAS:528:DyaK1cXivFKnur8%3D (Pubitemid 28227666)
11. K Kohno H Izumi T Uchiumi M Ashizuka M Kuwano 2003 The pleiotropic functions of the Y-box-binding protein, YB-1 Bioessays 25 7 691 698 10.1002/bies.10300 12815724 10.1002/bies.10300 1:CAS:528:DC%2BD3sXmtVKqt7g%3D (Pubitemid 36850797)
12. K Koike T Uchiumi T Ohga S Toh M Wada K Kohno M Kuwano 1997 Nuclear translocation of the Y-box binding protein by ultraviolet irradiation FEBS Lett 417 3 390 394 9409758 10.1016/S0014-5793(97)01296-9 1:CAS:528:DyaK2sXnt1ekurg%3D (Pubitemid 27511629)
13. Z Jia L Barbier H Stuart M Amraei S Pelech JW Dennis P Metalnikov P O'Donnell IR Nabi 2005 Tumor cell pseudopodial protrusions. Localized signaling domains coordinating cytoskeleton remodeling, cell adhesion, glycolysis, RNA translocation, and protein translation J Biol Chem 280 34 30564 30573 10.1074/jbc.M501754200 15985431 10.1074/jbc.M501754200 1:CAS:528: DC%2BD2MXos1Cqtr0%3D (Pubitemid 41216241)
14. J Wu C Lee D Yokom H Jiang MC Cheang E Yorida D Turbin IM Berquin PR Mertens T Iftner CB Gilks SE Dunn 2006 Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2 Cancer Res 66 9 4872 4879 10.1158/0008-5472.CAN-05-3561 16651443 10.1158/0008-5472. CAN-05-3561 1:CAS:528:DC%2BD28XjvF2kt7c%3D
15. A En-Nia E Yilmaz U Klinge DH Lovett I Stefanidis PR Mertens 2005 Transcription factor YB-1 mediates DNA polymerase alpha gene expression J Biol Chem 280 9 7702 7711 10.1074/jbc.M413353200 15615704 10.1074/jbc.M413353200 1:CAS:528:DC%2BD2MXhs1yisb8%3D (Pubitemid 40349663)
16. PR Mertens S Harendza AS Pollock DH Lovett 1997 Glomerular mesangial cell-specific transactivation of matrix metalloproteinase 2 transcription is mediated by YB-1 J Biol Chem 272 36 22905 22912 9278454 10.1074/jbc.272.36.22905 1:CAS:528:DyaK2sXlvFGhtLw%3D (Pubitemid 27386113)
17. M Kuwano Y Oda H Izumi SJ Yang T Uchiumi Y Iwamoto M Toi T Fujii H Yamana H Kinoshita T Kamura M Tsuneyoshi K Yasumoto K Kohno 2004 The role of nuclear Y-box binding protein 1 as a global marker in drug resistance Mol Cancer Ther 3 11 1485 1492 15542787 1:CAS:528:DC%2BD2cXpslCktb0%3D (Pubitemid 39562593)
18. Y Oda A Sakamoto N Shinohara T Ohga T Uchiumi K Kohno M Tsuneyoshi M Kuwano Y Iwamoto 1998 Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma Clin Cancer Res 4 9 2273 2277 9748149 1:CAS:528:DyaK1cXmslCjsb8%3D (Pubitemid 28415677)
19. Y Oda Y Ohishi T Saito E Hinoshita T Uchiumi N Kinukawa Y Iwamoto K Kohno M Kuwano M Tsuneyoshi 2003 Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma J Pathol 199 2 251 258 10.1002/path.1282 12533839 10.1002/path.1282 1:CAS:528:DC%2BD3sXhs1ynsrk%3D (Pubitemid 36176032)
20. M Janz N Harbeck P Dettmar U Berger A Schmidt K Jurchott M Schmitt HD Royer 2002 Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1 Int J Cancer 97 3 278 282 10.1002/ijc.1610 11774277 10.1002/ijc.1610 1:CAS:528:DC%2BD38XhvVWlsw%3D%3D (Pubitemid 34049016)
21. H Saji M Toi S Saji M Koike K Kohno M Kuwano 2003 Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma Cancer Lett 190 2 191 197 12565174 10.1016/S0304-3835(02)00590-6 1:CAS:528:DC%2BD3sXmsV2msQ%3D%3D (Pubitemid 36136018)
22. T Kamura H Yahata S Amada S Ogawa T Sonoda H Kobayashi M Mitsumoto K Kohno M Kuwano H Nakano 1999 Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? Cancer 85 11 2450 2454 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U 10357417 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2- U 1:STN:280:DyaK1M3osVejuw%3D%3D (Pubitemid 29244855)
23. H Yahata H Kobayashi T Kamura S Amada T Hirakawa K Kohno M Kuwano H Nakano 2002 Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer J Cancer Res Clin Oncol 128 11 621 626 10.1007/s00432-002-0386-6 12458343 10.1007/s00432-002-0386-6 1:CAS:528:DC%2BD3sXptVyhsA%3D%3D (Pubitemid 35435560)
24. Y Oda Y Ohishi Y Basaki H Kobayashi T Hirakawa N Wake M Ono K Nishio M Kuwano M Tsuneyoshi 2007 Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression Cancer Sci 98 7 1020 1026 10.1111/j.1349-7006.2007.00492.x 17459055 10.1111/j.1349-7006. 2007.00492.x 1:CAS:528:DC%2BD2sXnsVOqs78%3D (Pubitemid 46865386)
25. P Gimenez-Bonafe MN Fedoruk TG Whitmore M Akbari JL Ralph S Ettinger ME Gleave CC Nelson 2004 YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity Prostate 59 3 337 349 10.1002/pros.20023 15042610 10.1002/pros.20023 1:CAS:528:DC%2BD2cXkt12is7s%3D (Pubitemid 38509767)
26. RC Bargou K Jurchott C Wagener S Bergmann S Metzner K Bommert MY Mapara KJ Winzer M Dietel B Dorken HD Royer 1997 Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression Nat Med 3 4 447 450 9095180 10.1038/nm0497-447 1:CAS:528:DyaK2sXit1CqtLc%3D (Pubitemid 27145688)
27. T Fujita K Ito H Izumi M Kimura M Sano H Nakagomi K Maeno Y Hama K Shingu S Tsuchiya K Kohno M Fujimori 2005 Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel Clin Cancer Res 11 24 Pt 1 8837 8844 10.1158/1078-0432.CCR-05-0945 16361573 10.1158/1078-0432.CCR-05- 0945 1:CAS:528:DC%2BD2MXhtlWrsbbJ (Pubitemid 43005936)
28. M Yasen K Kajino S Kano H Tobita J Yamamoto T Uchiumi S Kon M Maeda G Obulhasim S Arii O Hino 2005 The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma Clin Cancer Res 11 20 7354 7361 10.1158/1078-0432.CCR- 05-1027 16243807 10.1158/1078-0432.CCR-05-1027 1:CAS:528:DC%2BD2MXhtFartbrI (Pubitemid 41507694)
29. K Shibahara K Sugio T Osaki T Uchiumi Y Maehara K Kohno K Yasumoto K Sugimachi M Kuwano 2001 Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer Clin Cancer Res 7 10 3151 3155 11595709 1:CAS:528:DC%2BD3MXnvF2rsrw%3D (Pubitemid 32963838)
30. D Faury A Nantel SE Dunn MC Guiot T Haque P Hauser M Garami L Bognar Z Hanzely PP Liberski E Lopez-Aguilar ET Valera LG Tone AS Carret RF Del Maestro M Gleave JL Montes T Pietsch S Albrecht N Jabado 2007 Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors J Clin Oncol 25 10 1196 1208 10.1200/JCO.2006.07.8626 17401009 10.1200/JCO.2006.07.8626 1:CAS:528:DC%2BD2sXkvFymsrY%3D (Pubitemid 46640565)
31. K Shibao H Takano Y Nakayama K Okazaki N Nagata H Izumi T Uchiumi M Kuwano K Kohno H Itoh 1999 Enhanced coexpression of YB-1 and DNA topoisomerase II alpha genes in human colorectal carcinomas Int J Cancer 83 6 732 737 10.1002/(SICI)1097-0215(19991210)83:6<732::AID-IJC6>3.0.CO;2-# 10597187 10.1002/(SICI)1097-0215(19991210)83:6<732::AID-IJC6>3.0.CO;2-# 1:CAS:528:DC%2BD3cXjtVyh
32. T Fujii A Kawahara Y Basaki S Hattori K Nakashima K Nakano K Shirouzu K Kohno T Yanagawa H Yamana K Nishio M Ono M Kuwano M Kage 2008 Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers Cancer Res 68 5 1504 1512 10.1158/0008-5472. CAN-07-2362 18316615 10.1158/0008-5472.CAN-07-2362 1:CAS:528: DC%2BD1cXislagu7k%3D (Pubitemid 351346859)
33. S Bergmann B Royer-Pokora E Fietze K Jurchott B Hildebrandt D Trost F Leenders JC Claude F Theuring R Bargou M Dietel HD Royer 2005 YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification Cancer Res 65 10 4078 4087 10.1158/0008-5472.CAN-04-4056 15899797 10.1158/0008-5472.CAN-04-4056 1:CAS:528:DC%2BD2MXktlSmsb8%3D (Pubitemid 40775644)
34. K To A Fotovati KM Reipas JH Law K Hu J Wang A Astanehe AH Davies L Lee AL Stratford A Raouf P Johnson IM Berquin HD Royer CJ Eaves SE Dunn 2010 Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance Cancer Res 70 7 2840 2851 10.1158/0008-5472.CAN-09-3155 20332234 10.1158/0008-5472.CAN-09-3155 1:CAS:528:DC%2BC3cXktFynt78%3D
35. G Habibi S Leung JH Law K Gelmon H Masoudi D Turbin M Pollak TO Nielsen D Huntsman SE Dunn 2008 Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes Breast Cancer Res 10 5 R86 10.1186/bcr2156 18925950 10.1186/bcr2156
36. O Gluz K Mengele M Schmitt R Kates R Diallo-Danebrock F Neff HD Royer N Eckstein S Mohrmann E Ting M Kiechle C Poremba U Nitz N Harbeck 2009 Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy J Clin Oncol 27 36 6144 6151 10.1200/JCO.2008.19.6261 19901122 10.1200/JCO.2008.19.6261 1:CAS:528:DC%2BC3cXht1agsb4%3D
37. E Dahl A En-Nia F Wiesmann R Krings S Djudjaj E Breuer T Fuchs PJ Wild A Hartmann SE Dunn PR Mertens 2009 Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer BMC Cancer 9 410 10.1186/1471-2407-9-410 19930682 10.1186/1471-2407-9-410
38. H Imachi K Murao H Dobashi MM Bhuyan X Cao K Kontani S Niki C Murazawa H Nakajima N Kohno H Yamashita H Iwase S Hayashi T Ishida A Yamauchi 2010 Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance Breast Cancer Res Treat 122 2 395 407 10.1007/s10549-009-0581-0 19847644 10.1007/s10549-009-0581-0 1:CAS:528:DC%2BC3cXnsFymtLc%3D
39. M Dalvai K Bystricky 2010 Cell cycle and anti-estrogen effects synergize to regulate cell proliferation and ER target gene expression PLoS One 5 6 e11011 10.1371/journal.pone.0011011 20543978 10.1371/journal.pone.0011011
40. T Sorlie CM Perou R Tibshirani T Aas S Geisler H Johnsen T Hastie MB Eisen M van de Rijn SS Jeffrey T Thorsen H Quist JC Matese PO Brown D Botstein P Eystein Lonning AL Borresen-Dale 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 19 10869 10874 10.1073/pnas.19136709898/19/10869 11553815 10.1073/pnas.191367098 1:CAS:528:DC%2BD3MXntVGmsbo%3D (Pubitemid 32878711)
41. LJ van 't Veer H Dai MJ van de Vijver YD He AA Hart M Mao HL Peterse K van der Kooy MJ Marton AT Witteveen GJ Schreiber RM Kerkhoven C Roberts PS Linsley R Bernards SH Friend 2002 Gene expression profiling predicts clinical outcome of breast cancer Nature 415 6871 530 536 10.1038/415530a415530a 10.1038/415530a (Pubitemid 34130608)
42. S Paik S Shak G Tang C Kim J Baker M Cronin FL Baehner MG Walker D Watson T Park W Hiller ER Fisher DL Wickerham J Bryant N Wolmark 2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 27 2817 2826 10.1056/NEJMoa041588 15591335 10.1056/NEJMoa041588 1:CAS:528:DC%2BD2MXhslymsw%3D%3D (Pubitemid 40051905)
43. JS Parker M Mullins MC Cheang S Leung D Voduc T Vickery S Davies C Fauron X He Z Hu JF Quackenbush IJ Stijleman J Palazzo JS Marron AB Nobel E Mardis TO Nielsen MJ Ellis CM Perou PS Bernard 2009 Supervised risk predictor of breast cancer based on intrinsic subtypes J Clin Oncol 27 8 1160 1167 10.1200/JCO.2008.18.1370 19204204 10.1200/JCO.2008.18.1370
44. CA Zahnow 2006 ErbB receptors and their ligands in the breast Expert Rev Mol Med 8 23 1 21 10.1017/S146239940600010X 16984691 10.1017/S146239940600010X (Pubitemid 44463426)
45. RI Nicholson IR Hutcheson HE Jones SE Hiscox M Giles KM Taylor JM Gee 2007 Growth factor signalling in endocrine and anti-growth factor resistant breast cancer Rev Endocr Metab Disord 8 3 241 253 10.1007/s11154-007-9033-5 17486454 10.1007/s11154-007-9033-5 1:CAS:528:DC%2BD2sXhtFWru7nE (Pubitemid 47524867)
46. A Sommer J Hoffmann RB Lichtner MR Schneider K Parczyk 2003 Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines J Steroid Biochem Mol Biol 85 1 33 47 12798355 10.1016/S0960-0760(03)00139-0 1:CAS:528:DC%2BD3sXksVGntb0%3D (Pubitemid 36694275)
47. T Bouras MC Southey DJ Venter 2001 Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu Cancer Res 61 3 903 907 11221879 1:CAS:528:DC%2BD3MXhsFSrtbY%3D (Pubitemid 32174400)
48. T Kirkegaard LM McGlynn FM Campbell S Muller SM Tovey B Dunne KV Nielsen TG Cooke JM Bartlett 2007 Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients Clin Cancer Res 13 5 1405 1411 10.1158/1078-0432.CCR-06-1933 17332282 10.1158/1078-0432.CCR-06-1933 1:CAS:528:DC%2BD2sXitlSjtro%3D (Pubitemid 46450429)
49. T Lahusen RT Henke BL Kagan A Wellstein AT Riegel 2009 The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer Breast Cancer Res Treat 116 2 225 237 10.1007/s10549-009-0405-2 19418218 10.1007/s10549-009-0405-2 1:CAS:528:DC%2BD1MXntF2nt74%3D
50. M Fan PS Yan C Hartman-Frey L Chen H Paik SL Oyer JD Salisbury AS Cheng L Li PH Abbosh TH Huang KP Nephew 2006 Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant Cancer Res 66 24 11954 11966 10.1158/0008-5472.CAN-06-1666 17178894 10.1158/0008-5472.CAN-06-1666 1:CAS:528:DC%2BD28Xhtlagu7jK (Pubitemid 46094209)
51. RA McClelland D Barrow TA Madden CM Dutkowski J Pamment JM Knowlden JM Gee RI Nicholson 2001 Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182, 780 (Faslodex) Endocrinology 142 7 2776 2788 11415996 10.1210/en.142.7.2776 1:CAS:528:DC%2BD3MXkslels7o%3D (Pubitemid 32575512)
52. T Frogne JS Jepsen SS Larsen CK Fog BL Brockdorff AE Lykkesfeldt 2005 Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth Endocr Relat Cancer 12 3 599 614 10.1677/erc.1.00946 16172194 10.1677/erc.1.00946 1:CAS:528:DC%2BD2MXht1Sjsr3P (Pubitemid 41482995)
53. Z Gu RY Lee TC Skaar KB Bouker JN Welch J Lu A Liu Y Zhu N Davis F Leonessa N Brunner Y Wang R Clarke 2002 Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182, 780) Cancer Res 62 12 3428 3437 12067985 1:CAS:528:DC%2BD38XkslWqsbo%3D (Pubitemid 34651389)
54. T Ohga T Uchiumi Y Makino K Koike M Wada M Kuwano K Kohno 1998 Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene J Biol Chem 273 11 5997 6000 9497311 10.1074/jbc.273.11.5997 1:CAS:528:DyaK1cXitFamurc%3D (Pubitemid 28144673)
55. U Stein S Bergmann GL Scheffer RJ Scheper HD Royer PM Schlag W Walther 2005 YB-1 facilitates basal and 5-fluorouracil-inducible expression of the human major vault protein (MVP) gene Oncogene 24 22 3606 3618 10.1038/sj.onc.1208386 15750632 10.1038/sj.onc.1208386 1:CAS:528:DC%2BD2MXktlWisLw%3D (Pubitemid 40756230)
56. A Goldhirsch JH Glick RD Gelber AS Coates B Thurlimann HJ Senn 2005 Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005 Ann Oncol 16 10 1569 1583 10.1093/annonc/mdi326 16148022 10.1093/annonc/mdi326 1:STN:280:DC%2BD2MvpvFKhsA%3D%3D (Pubitemid 41511089)
57. Law JH, Li Y, To K, Wang M, Astanehe A, Lambie K, Dhillon J, Jones SJ, Gleave ME, Eaves CJ, Dunn SE (2010) Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability. PLoS One 5 (9). doi: 10.1371/journal.pone.0012661